Shots:

• The transaction provides Cytokinetics with $250M at closing making up to $575M of total deal value
• The company will receive commercial launch funding of $50M plus $175M within a year of Aficamten approval in oHCM for 10yrs. in quarterly tranches (totalling 1.9x). 4.5% & 1% royalties on up to $5B & >$5B annual net sales, respectively. Royalty Pharma will also buy $50M of Cytokinetics' common stock
• Cytokinetics to get $100M & $50M funding for omecamtiv mecarbil’s P-III & CK-586’s P-II in heart failure, respectively, & receive option funding of ~$150M in CK-586’s P-III. Royalty Pharma will get $100M plus 2% royalty on omecamtiv mecarbil’s P-III trial success & FDA approval in definite time-frame whereas on failure it will receive ~$237.5M for 18-22 quarters; $150M milestones upon CK-586’s FDA approval & 4.5% royalty. 1% royalty on CK-586 sales, if opt-out to fund P-III

Ref: Cytokinetics | Image: Cytokinetics

Related News:- Cytokinetics Reports Results from the P-III (SEQUOIA-HCM) Study of Aficamten for Obstructive Hypertrophic Cardiomyopathy

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com